The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis - Procalcitonin, Presepsin. Correlation With Blood Culture and Detection of Infection by Molecular Biological Methods
Sponsor: Charles University, Czech Republic
Listed as NCT03314831, this observational or N/A phase trial focuses on Sepsis Syndrome and Systemic Inflammatory Response Syndrome and remains completed. Sponsored by Charles University, Czech Republic, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Mar 2023 — Jul 2024 [monthly]
Completed
Status: Unknown Status → Completed
-
Oct 2021 — Mar 2023 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting
▶ Show 5 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Recruiting
-
Jun 2018 — Jun 2019 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Nov 2017 — Feb 2018 [monthly]
Not Yet Recruiting NA
First recorded
Oct 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Charles University, Czech Republic
For direct contact, visit the study record on ClinicalTrials.gov .